Mereo BioPharma (MREO) Other Non-Current Liabilities (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Other Non-Current Liabilities of $362000.0 for Q1 2026, down 13.6% year-on-year from $419000.0 in Q1 2025, and down 45.23% on a QoQ basis from $661000.0 in Q4 2025.
Mereo BioPharma (MREO) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Other Non-Current Liabilities for 10 consecutive years, with $362000.0 the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 13.6% year-over-year to $362000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $362000.0 (down 13.6% YoY) and the FY2025 annual result came in at $661000.0, down 19.49% from the prior year.
- Other Non-Current Liabilities slipped to $362000.0 in Q1 2026 per MREO's latest filing, from $661000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for MREO reached as high as $9.0 million in Q2 2022 and fell as low as $362000.0 in Q1 2026.
- A 5-year average of $1.3 million and a median of $661000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities sank 94.46% — and 2024, when it jumped 79.85%.
- Year by year, Other Non-Current Liabilities stood at $622824.9 in 2022, then grew by 22.67% to $764000.0 in 2023, then climbed by 7.46% to $821000.0 in 2024, then slipped by 19.49% to $661000.0 in 2025, then slumped by 45.23% to $362000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $362000.0, $661000.0, and $652000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Mereo BioPharma | 232.52 Mn | 232.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 362,000.00 |
| Dec 31, 2025 | 661,000.00 |
| Sep 30, 2025 | 652,000.00 |
| Jun 30, 2025 | 545,000.00 |
| Mar 31, 2025 | 419,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 925,000.00 |
| Mar 31, 2024 | 855,000.00 |
| Dec 31, 2023 | 764,000.00 |
| Jun 30, 2023 | 514,310.26 |
| Dec 31, 2022 | 622,824.94 |
| Jun 30, 2022 | 8.97 Mn |
| Dec 31, 2021 | 11.24 Mn |
| Jun 30, 2021 | 47.54 Mn |
| Dec 31, 2020 | 67.05 Mn |
| Jun 30, 2020 | 44.40 Mn |
| Dec 31, 2019 | 168,429.96 |
| Jun 30, 2019 | 2.48 Mn |
| Dec 31, 2018 | 1.29 Mn |